Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-07-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于SAL0120片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0120). It includes details about the drug, regulatory acceptance, and future steps. The document is short (1391 characters) and serves as an official notice of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It is an announcement of a regulatory acceptance related to drug clinical trials, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-07-14 Chinese
关于S086上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a drug listing application (S086) by the National Medical Products Administration. It contains no financial data, no detailed financial statements, nor any report or presentation content. It is a regulatory announcement about the acceptance of a drug registration application, not a financial report or management discussion. The document is short (933 characters) and serves as an official notice of acceptance of an application, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-07-07 Chinese
关于SAL0119药品临床试验申请获得FDA受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0119) by the FDA. It contains no financial data, no financial statements, and no detailed report content. The document is short (1313 characters) and serves to inform investors and the public about a regulatory milestone related to drug development. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a clinical trial application acceptance, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category.
2023-06-25 Chinese
关于向参股公司普瑞基准科技（北京）有限公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Xilintai Pharmaceutical Co., Ltd. regarding an increase in investment in an associate company, Pru Benchmark Technology (Beijing) Co., Ltd. It includes transaction overview, board approval, parties involved, shareholding structure before and after the transaction, financial data of the associate, terms of the investment agreement, risk disclosures, and other related information. The document is a formal announcement about a capital increase transaction involving equity investment in an associate company. It is not a full financial report, audit report, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits the category of Capital/Financing Update as it provides detailed information about the company's financing activity (capital increase in an associate).
2023-06-20 Chinese
第五届董事会第三十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the approval of an investment in an associate company and the authorization given to management to execute the transaction. The document includes meeting attendance, voting results, and references to related announcements. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board decision, which fits the category of Board/Management Information (MANG). The document length is short and focused on a specific board resolution, confirming it is not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-06-20 Chinese
关于第二期员工持股计划第二个锁定期届满的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the second lock-up period expiration of the company's second employee stock ownership plan. It discusses the plan's background, stock sources, lock-up periods, unlocking proportions, and subsequent arrangements. It does not contain financial statements or quarterly/yearly financial results but focuses on employee stock plan details and regulatory compliance related to stock unlocking and trading restrictions. This fits the category of Capital/Financing Update (CAP), as it relates to employee stock ownership plans and share capital management rather than a full financial report or other categories.
2023-06-15 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.